Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01286272 · ClinicalTrials.gov registry record · Phase 2
Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 135
- Enrollment target
NCT01286272: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01286272 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 135 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01286272, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 135 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well ofatumumab and bendamustine hydrochloride with or without bortezomib works in treating patients with untreated follicular non-Hodgkin lymphoma. Monoclonal antibodies, such as ofatumumab, may block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Bortezomib may also stop the growth of cancer cells by blocking blood flow to the tumor. It is not yet known whether ofatumumab and bendamustine hydrochloride are more effective with bortezomib in treating patients with follicular non-Hodgkin lymphoma.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Bortezomib
- RADIATION Fludeoxyglucose F-18
- DRUG Bendamustine Hydrochloride
- BIOLOGICAL Ofatumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2011-04-28 |
| Est. Completion | 2025-09-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01286272
The ClinicalTrials.gov registry entry for NCT01286272 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01286272 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01286272 about?
NCT01286272 is a clinical study titled "Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma". This randomized phase II trial studies how well ofatumumab and bendamustine hydrochloride with or without bortezomib works in treating patients with untreated follicular non-Hodgkin lymphoma. Monoclonal antibodies, such as ofatumumab, may block cancer growth in different ways by targeting certain ce...
What is the current status of trial NCT01286272?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 135 participants. The study started on 2011-04-28. Estimated completion is 2025-09-02.
What interventions are being tested in trial NCT01286272?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Bortezomib (DRUG), Fludeoxyglucose F-18 (RADIATION), Bendamustine Hydrochloride (DRUG), Ofatumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01286272?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.